Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
75
BIOA Quote, Financials, Valuation and Earnings
Last price:
$13.90
Seasonality move
:
7.25%
Day range:
$13.38 - $14.46
52-week range:
$2.88 - $14.46
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
85.31x
P/B ratio:
1.82x
Volume:
196.9K
Avg. volume:
393.6K
1-year change:
131.58%
Market cap:
$504.8M
Revenue:
--
EPS (TTM):
-$2.11
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BIOA
BioAge Labs, Inc.
|
$777.5K | -$0.51 | -63.01% | -9.88% | $12.00 |
|
CATX
Perspective Therapeutics, Inc.
|
$206.8K | -$0.32 | -9.65% | -37.91% | $12.3077 |
|
ELMD
Electromed, Inc.
|
$16.6M | -- | 11.04% | -- | $36.00 |
|
MYO
Myomo, Inc.
|
$9.4M | -$0.11 | -13.8% | -1168.66% | $5.00 |
|
VNRX
VolitionRX Ltd.
|
$715.6K | -$0.05 | 272.5% | -33.67% | $2.20 |
|
XTNT
Xtant Medical Holdings, Inc.
|
$32.7M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BIOA
BioAge Labs, Inc.
|
$14.08 | $12.00 | $504.8M | -- | $0.00 | 0% | 85.31x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8100 | $12.3077 | $208.9M | -- | $0.00 | 0% | 190.53x |
|
ELMD
Electromed, Inc.
|
$28.73 | $36.00 | $239.6M | 30.91x | $0.00 | 0% | 3.83x |
|
MYO
Myomo, Inc.
|
$1.02 | $5.00 | $39.2M | -- | $0.00 | 0% | 1.00x |
|
VNRX
VolitionRX Ltd.
|
$0.25 | $2.20 | $30.9M | -- | $0.00 | 0% | 17.27x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.78 | $1.50 | $108.9M | 76.27x | $0.00 | 0% | 0.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BIOA
BioAge Labs, Inc.
|
2.51% | 3.090 | 3.38% | 11.69x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
ELMD
Electromed, Inc.
|
-- | 1.217 | -- | 4.58x |
|
MYO
Myomo, Inc.
|
45.68% | -2.855 | 35.87% | 1.94x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.566 | 15.4% | 0.04x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 2.955 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BIOA
BioAge Labs, Inc.
|
$2M | -$23.1M | -24.18% | -24.89% | -1126.58% | -$16.1M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
ELMD
Electromed, Inc.
|
$13.2M | $2.7M | 18.88% | 18.89% | 15.81% | -$98K |
|
MYO
Myomo, Inc.
|
$6.4M | -$3.5M | -46.49% | -68.35% | -34.86% | -$2.9M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
BioAge Labs, Inc. vs. Competitors
-
Which has Higher Returns BIOA or CATX?
Perspective Therapeutics, Inc. has a net margin of -982.04% compared to BioAge Labs, Inc.'s net margin of -12425.36%. BioAge Labs, Inc.'s return on equity of -24.89% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital BIOABioAge Labs, Inc.97.61% -$0.56 $284.6M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About BIOA or CATX?
BioAge Labs, Inc. has a consensus price target of $12.00, signalling downside risk potential of -14.77%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 338%. Given that Perspective Therapeutics, Inc. has higher upside potential than BioAge Labs, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than BioAge Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIOABioAge Labs, Inc.1 3 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is BIOA or CATX More Risky?
BioAge Labs, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock BIOA or CATX?
BioAge Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioAge Labs, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIOA or CATX?
BioAge Labs, Inc. quarterly revenues are $2.1M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. BioAge Labs, Inc.'s net income of -$20.2M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, BioAge Labs, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioAge Labs, Inc. is 85.31x versus 190.53x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOABioAge Labs, Inc.85.31x -- $2.1M -$20.2M CATXPerspective Therapeutics, Inc.190.53x -- $209K -$26M
-
Which has Higher Returns BIOA or ELMD?
Electromed, Inc. has a net margin of -982.04% compared to BioAge Labs, Inc.'s net margin of 12.65%. BioAge Labs, Inc.'s return on equity of -24.89% beat Electromed, Inc.'s return on equity of 18.89%.
Company Gross Margin Earnings Per Share Invested Capital BIOABioAge Labs, Inc.97.61% -$0.56 $284.6M ELMDElectromed, Inc.78.15% $0.25 $44.7M -
What do Analysts Say About BIOA or ELMD?
BioAge Labs, Inc. has a consensus price target of $12.00, signalling downside risk potential of -14.77%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25.31%. Given that Electromed, Inc. has higher upside potential than BioAge Labs, Inc., analysts believe Electromed, Inc. is more attractive than BioAge Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIOABioAge Labs, Inc.1 3 0 ELMDElectromed, Inc.4 0 0 -
Is BIOA or ELMD More Risky?
BioAge Labs, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.
-
Which is a Better Dividend Stock BIOA or ELMD?
BioAge Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioAge Labs, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIOA or ELMD?
BioAge Labs, Inc. quarterly revenues are $2.1M, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. BioAge Labs, Inc.'s net income of -$20.2M is lower than Electromed, Inc.'s net income of $2.1M. Notably, BioAge Labs, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioAge Labs, Inc. is 85.31x versus 3.83x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOABioAge Labs, Inc.85.31x -- $2.1M -$20.2M ELMDElectromed, Inc.3.83x 30.91x $16.9M $2.1M
-
Which has Higher Returns BIOA or MYO?
Myomo, Inc. has a net margin of -982.04% compared to BioAge Labs, Inc.'s net margin of -36.3%. BioAge Labs, Inc.'s return on equity of -24.89% beat Myomo, Inc.'s return on equity of -68.35%.
Company Gross Margin Earnings Per Share Invested Capital BIOABioAge Labs, Inc.97.61% -$0.56 $284.6M MYOMyomo, Inc.63.84% -$0.09 $26.9M -
What do Analysts Say About BIOA or MYO?
BioAge Labs, Inc. has a consensus price target of $12.00, signalling downside risk potential of -14.77%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 390.2%. Given that Myomo, Inc. has higher upside potential than BioAge Labs, Inc., analysts believe Myomo, Inc. is more attractive than BioAge Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIOABioAge Labs, Inc.1 3 0 MYOMyomo, Inc.4 0 0 -
Is BIOA or MYO More Risky?
BioAge Labs, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.
-
Which is a Better Dividend Stock BIOA or MYO?
BioAge Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioAge Labs, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIOA or MYO?
BioAge Labs, Inc. quarterly revenues are $2.1M, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. BioAge Labs, Inc.'s net income of -$20.2M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, BioAge Labs, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioAge Labs, Inc. is 85.31x versus 1.00x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOABioAge Labs, Inc.85.31x -- $2.1M -$20.2M MYOMyomo, Inc.1.00x -- $10.1M -$3.7M
-
Which has Higher Returns BIOA or VNRX?
VolitionRX Ltd. has a net margin of -982.04% compared to BioAge Labs, Inc.'s net margin of -862.39%. BioAge Labs, Inc.'s return on equity of -24.89% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BIOABioAge Labs, Inc.97.61% -$0.56 $284.6M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About BIOA or VNRX?
BioAge Labs, Inc. has a consensus price target of $12.00, signalling downside risk potential of -14.77%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 773.02%. Given that VolitionRX Ltd. has higher upside potential than BioAge Labs, Inc., analysts believe VolitionRX Ltd. is more attractive than BioAge Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIOABioAge Labs, Inc.1 3 0 VNRXVolitionRX Ltd.4 2 0 -
Is BIOA or VNRX More Risky?
BioAge Labs, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.
-
Which is a Better Dividend Stock BIOA or VNRX?
BioAge Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioAge Labs, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIOA or VNRX?
BioAge Labs, Inc. quarterly revenues are $2.1M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. BioAge Labs, Inc.'s net income of -$20.2M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, BioAge Labs, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioAge Labs, Inc. is 85.31x versus 17.27x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOABioAge Labs, Inc.85.31x -- $2.1M -$20.2M VNRXVolitionRX Ltd.17.27x -- $627.3K -$5.4M
-
Which has Higher Returns BIOA or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -982.04% compared to BioAge Labs, Inc.'s net margin of 3.93%. BioAge Labs, Inc.'s return on equity of -24.89% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital BIOABioAge Labs, Inc.97.61% -$0.56 $284.6M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About BIOA or XTNT?
BioAge Labs, Inc. has a consensus price target of $12.00, signalling downside risk potential of -14.77%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 92.8%. Given that Xtant Medical Holdings, Inc. has higher upside potential than BioAge Labs, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than BioAge Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIOABioAge Labs, Inc.1 3 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is BIOA or XTNT More Risky?
BioAge Labs, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.
-
Which is a Better Dividend Stock BIOA or XTNT?
BioAge Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioAge Labs, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIOA or XTNT?
BioAge Labs, Inc. quarterly revenues are $2.1M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. BioAge Labs, Inc.'s net income of -$20.2M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, BioAge Labs, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioAge Labs, Inc. is 85.31x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOABioAge Labs, Inc.85.31x -- $2.1M -$20.2M XTNTXtant Medical Holdings, Inc.0.85x 76.27x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
GLTO alert for Dec 26
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 1.54% over the past day.
Sell
27
CDNAF alert for Dec 26
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
